Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a tim…
Medical - Devices
US, Acton [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -68.84 | 164.65 | 528.36 | |
| Graham Fair Price | -26.75 | 13.68 | 18.68 | |
| PEG | 211.22 | -1.14 | 0.37 | |
| Price/Book | -28.11 | 14.87 | 20.69 | |
| Price/Cash Flow | -83.78 | 184.90 | 1139.72 | |
| Prices/Earnings | 55.61 | 57.09 | 36.68 | |
| Price/Sales | -10.46 | 26.62 | 29.73 | |
| Price/FCF | -83.78 | 184.90 | 1139.72 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Bad
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -0.97 | 0.70 | 0.71 | |
| Operating Margin | -46.95 | 0.13 | 0.24 | |
| ROA | -50.83 | 0.02 | 0.04 | |
| ROE | 0.14 | 0.07 | -53.80 | |
| ROIC | 0.06 | 0.02 | -61.95 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.03 | 0.02 | 63.28 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 1.26 | -0.54 | -57.08 | |
| EPS QOQ | 1.00 | -0.50 | -50.00 | |
| FCF QOQ | -0.60 | 3.78 | 525.98 | |
| Revenue QOQ | 0.18 | -0.13 | -25.03 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 243.84 | 294.04 | 20.59 | |
| Days Sales Outstanding (DSO) | 63.50 | 65.30 | 2.84 | |
| Inventory Turnover | 0.37 | 0.31 | -17.07 | |
| Debt/Capitalization | 0.66 | 0.64 | -3.06 | |
| Quick Ratio | 2.36 | 2.48 | 5.11 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 10.49 | 11.30 | 7.77 | |
| Cash | 10.08 | 10.74 | 6.53 | |
| Capex | -0.45 | -0.34 | 24.16 | |
| Free Cash Flow | 0.19 | 0.91 | 377.53 | |
| Revenue | 7.30 | 6.31 | -13.48 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad